Multiparametric analysis of the relationship between tumor hypoxia and perfusion with 18F-fluoroazomycin arabinoside and 15O-H2O PET

Journal of Nuclear Medicine

Volumn 57, Issue 4, 2016, Pages 530-535

  Iqbal, Ramsha ^a   Kramer, Gem M ^a   Verwer, Eline E ^a   Huisman, Marc C ^a   De Langen, Adrianus J ^a   Bahce, Idris ^a   Van Velden, Floris H P ^a   Windhorst, Albert D ^a   Lammertsma, Adriaan A ^a   Hoekstra, Otto S ^a   Boellaard, Ronald ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FAZA; Hypoxia; Non small cell lung cancer; Perfusion; PET

Indexed keywords

FLUOROAZOMYCIN ARABINOSIDE F 18; TRACER; UNCLASSIFIED DRUG; WATER 15 O; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; RADIOPHARMACEUTICAL AGENT; WATER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NON SMALL CELL LUNG CANCER; ONCOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR HYPOXIA; TUMOR PERFUSION; TUMOR VOLUME; AGED; ANOXIA; BLOOD FLOW; CHEMISTRY; CLUSTER ANALYSIS; COMPARATIVE STUDY; LUNG TUMOR; METABOLISM; MIDDLE AGED; NEOPLASM; SCINTISCANNING; VASCULARIZATION;

AGED; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; CLUSTER ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; NITROIMIDAZOLES; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; WATER;

EID: 84963959712     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.166579     Document Type: Article

References (30)

1. Verwer EE, Boellaard R, Van der Veldt AM. Positron emission tomography to assess hypoxia and perfusion in lung cancer. World J Clin Oncol. 2014;5:824-844.
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225-239.
3. 18F-FAZA)-PET: a review. Clin Nucl Med. 2014;39:44-48.
4. Krause BJ, Beck R, Souvatzoglou M, et al. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging. 2006;50:28-43.
5. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54:921-927.
6. 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. J Med Imaging Radiat Oncol. 2013;57: 475-481.
7. Arabi M, Piert M. Hypoxia PET/CT imaging: implications for radiation oncology. Q J Nucl Med Mol Imaging. 2010;54:500-509.
8. Wijsman R, Kaanders JHAM, Oyen WJG, et al. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. Q J Nucl Med Mol Imaging. 2013;57:244-256.
9. Vaupel P, Harrison L. Tumour hypoxia: causative factors, compensatory mechanisms and cellular response. Oncologist. 2004;9:4-9.
10. 18F-FAZA kinetics in non-small cell lung cancer patients. J Nucl Med. 2014;55:1772-1777.
11. van der Veldt AA, Hendrikse NH, Harms HJ, et al. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med. 2010;51:1684-1690.
12. Lodge MA, Carson RE, Carrasquillo JA, Whatley M, Libutti SK, Bacharach SL. Parametric images of blood flow in oncology PET studies using 15O-water. J Nucl Med. 2000;41:1784-1792.
13. Boellaard R, Knaapen P, Rijbroek A, Luurtsema GJJ, Lammertsma AA. Evaluation of basis function and linear least squares methods for generating parametric blood flow images using 15O-water and positron emission tomography. Mol Imaging Biol. 2005;7:273-285.
14. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab. 1993;13:15-23.
15. 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369-378.
16. 18F-FMISO PET data to analyse tumour hypoxia. Phys Med Biol. 2005;50:2209-2224.
17. 18F-FAZA and 15O-H2O in patients with head and neck tumors. J Nucl Med. 2010;51:1386-1394.
18. Grönroos TJ, Lehtiö K, Söderström K, et al. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer. 2014;14: 876-887.
19. 18F-fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652.
20. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49: 6449-6465.
21. Lopci E, Grassi I, Chiti A, et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging. 2014;4:365-384.
22. 18F-fluoromisonidazole and 15O-H2O. J Nucl Med. 2004;45:1851-1859.
23. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumours. Neoplasia. 1999;1:197-207.
24. 18F-FAZA and 125I-gluco-RGD autoradiography. J Nucl Med. 2008;49:597-605.
25. 18F-FMISO PETguided intratumoral pO2 measurements. Med Phys. 2009;36:5301-5309.
26. 18FFAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiother Oncol. 2012;105:29-35.
27. 18FFAZA in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:1523-1531.
28. Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts S. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med. 2014;55:515-521.
29. 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med. 2013;54:1175-1180.
30. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235-242.